alexa Gene Therapy for Articular Cartilage Repair | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Gene Therapy for Articular Cartilage Repair

Tong Ming Liu*

Stem Cell and Developmental Biology, Genome Institute of Singapore, P. O. Box-138672, Singapore

*Corresponding Author:
Tong Ming Liu, PhD
Stem Cell and Developmental Biology
Genome Institute of Singapore, P. O. Box-138672, Singapore
Tel: 65 6808-8229
Fax: 65 6808-8308
E-mail: [email protected]

Received Date: June 21, 2012; Accepted Date: June 23, 2012; Published Date: June 25, 2012

Citation: Liu TM (2012) Gene Therapy for Articular Cartilage Repair. Pharmaceut Anal Acta 3:e112. doi: 10.4172/2153-2435.1000e112

Copyright: © 2012 Liu TM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta

Gene therapy offers a promising treatment option for repair of damaged articular cartilage, an unsolved problem in modern orthopaedics. Articular cartilage is a highly specialized tissue composing of chondrocytes and extracellular matrix (ECM). As the gliding surface of joints, healthy articular cartilage allows for smooth and painless joint motion. However, cartilage diseases are most commonly seen due to traumatic injury and degenerative diseases, which cause pain and dysfunction. Due to avascular status, articular cartilage has a very limited capacity for self-repair and regeneration. Current surgical therapeutic procedures for cartilage repair fail to restore a normal articular surface [1-5]. Gene therapy is being developed to generate long-lasting hyaline cartilage by augmenting the reparative activities or preventing the degenerative activities.

Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. The first gene therapy for articular tissues was described to treat human rheumatoid arthritis [6]. Although considerable progress has been made in identifying genes that regulate cartilage differentiation in past 15 years, gene therapy to repair full-thickness cartilage defects is unsatisfactory. Genes used for cartilage repair include growth factor genes, cytokine receptor antagonists and transcription factors. Growth factors improve cartilage repair by stimulating chondrocyte proliferation and improve chondrogenesis [7-12]. Cytokine receptor antagonist IL-1Rα and tumor necrosis factor alpha inhibitor prevent cartilage matrix degradation and reduce inflammation to prevent arthritis [13-17]. Transcription factors are useful in cartilage repair by promoting chondrogenesis or maintaining chondrocyte phenotype [18-20]. Current gene therapy approaches can be achieved by either administering the desired genes into the sites of damaged cartilage, or by transplantation of genetically modified cells into the defects. The selection of gene delivery approaches depends on the need of longterm or short-term expression and the therapeutic expression level of the desired genes.

Multiple gene therapy combined with stem cells and scaffold is desirable and need to be developed for repair of articular cartilage defects. The optimal choice of therapeutic genes for cell-based cartilage repair cannot be simply predicted from observations of individual genes [21]. More efforts need to be made to understand the molecular basis of cartilage differentiation. So far, gene network of cartilage differentiation remains poorly understood, the molecular mechanism and the role of genes during cartilage differentiation are not well defined; the therapeutic genes identified for articular cartilage are very limited. It is still challenging to deliver the therapeutic genes to the damaged cartilage in a safe, efficient manner and express them in a controllable manner. Taking sox9 as an example, the chondrogenic master regulator sox9 is required for MSC commitment and condensation, and chondrocyte differentiation and proliferation. However, Sox9 inhibits transition of proliferating chondrocytes to hypertrophy [19]. Expression level of sox9 is also critical to chondrocyte, low levels of Sox9 overexpression enhanced Col2A1 gene transcription whereas high levels of Sox9 overexpression induced an inhibition of Col2A1 gene expression in chondrocytes [22]. These data suggest that continuous expression of sox9 is not good for hyaline articular cartilage, controllable expression of sox9 will be of particular importance to regeneration of hyaline cartilage. Therefore, efficient delivery and controllable expression of the therapeutic genes, and multiple strategies will lead to complete and durable hyaline cartilage regeneration.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 11608
  • [From(publication date):
    July-2012 - Dec 13, 2017]
  • Breakdown by view type
  • HTML page views : 7831
  • PDF downloads : 3777
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version